American Association for Cancer Research
00085472can110804-sup-supplementary_figure_1_pdf_4047k.pdf (3.95 MB)

Supplementary Figure 1 from Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine

Download (3.95 MB)
journal contribution
posted on 2023-03-30, 20:30 authored by Basav N. Hangalapura, Dinja Oosterhoff, Jan de Groot, Louis Boon, Thomas Tüting, Alfons J. van den Eertwegh, Winald R. Gerritsen, Victor W. van Beusechem, Alexander Pereboev, David T. Curiel, Rik J. Scheper, Tanja D. de Gruijl

PDF file - 4047K



In situ delivery of tumor-associated antigen (TAA) genes into dendritic cells (DC) has great potential as a generally applicable tumor vaccination approach. Although adenoviruses (Ad) are an attractive vaccine vehicle in this regard, Ad-mediated transduction of DCs is hampered by the lack of expression of the Ad receptor CAR on the DC surface. DC activation also requires interaction of CD40 with its ligand CD40L to generate protective T-cell–mediated tumor immunity. Therefore, to create a strategy to target Ads to DCs in vivo, we constructed a bispecific adaptor molecule with the CAR ectodomain linked to the CD40L extracellular domain via a trimerization motif (CFm40L). By targeting Ad to CD40 with the use of CFm40L, we enhanced both transduction and maturation of cultured bone marrow–derived DCs. Moreover, we improved transduction efficiency of DCs in lymph node and splenic cell suspensions in vitro and in skin and vaccination site–draining lymph nodes in vivo. Furthermore, CD40 targeting improved the induction of specific CD8+ T cells along with therapeutic efficacy in a mouse model of melanoma. Taken together, our findings support the use of CD40-targeted Ad vectors encoding full-length TAA for in vivo targeting of DCs and high-efficacy induction of antitumor immunity. Cancer Res; 71(17); 5827–37. ©2011 AACR.

Usage metrics

    Cancer Research



    Ref. manager